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More than 95% of human immunodeficiency virus (HIV) 
pediatric infections are the result of vertical transmission 
from mother to child during pregnancy, intrapartum, or 
in developing countries, through breastfeeding. Anti- 
retroviral therapy, elective cesarean section and no breast- 
feeding have reduced the rate of transmission below 5%. l 
In the Infectious Diseases Unit of Careggi Hospital, 
Firenze, Italy, between 1997 and 1999,18 HIV-l infected 
pregnant women gave birth to 24 children. All the preg- 
nant women received antiretroviral therapy: zidovudine 
(ZDV) in four cases, two nucleoside reverse transcriptase 
inhibitors (NRTI) in eight cases, two NRTI combined with 
protease inhibitors (PI) in five cases, and two NRTI com- 
bined with nevirapine (NW) in two cases (patient 4 
switched from nellinavir to nevirapine). The antiretro- 
viral preferred regimen in three women did not include 
ZDV Eight infected pregnant women delivered vaginally, 
whereas the others delivered by elective cesarean sec- 
tion. In every case, intravenous ZDV was given intra- 
partum and ZDV syrup was given to infants, as per AIDS 
Clinical Trial Group (ACTG) 076 protocol.’ 
Table 1 shows CD4 cell counts (last value before 
delivery), HIV RNA (last value before delivery), anti- 
retroviral regimen, and mode of delivery of the infected 
pregnant women. Mother-to-child transmission of HIV-l 
occurred in only 1 of 18 treated pregnant women (first 
pregnancy of patient 1). In the infant, HIV polymerase 
chain reaction (PCR) was found to be positive at 1 week 
of age; the infected newborn girl was small for gestational 
age and affected by trisomy 18, a chromosomal disorder 
producing many developmental abnormalities. In this 
case, a three-part regimen of ZDV, as per ACTG 076 pro- 
tocol,2 and elective cesarean section were carried out. 
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The antiretroviral regimen in patient 1 (2nd preg- 
nancy), patient 5, and patient 8 did not include ZDV, 
because of HIV-l ZDV-resistant strains; genotypic analysis 
detected gene mutation 70R in patient 1 and patient 8 
and detected gene mutations 41Lw, 67N, 2 15w, 70R, 2 19Q 
in patient 5. Stavudine (d4T) + lamivudine (3TC) was the 
therapeutic regimen, started at 14 weeks, preferred for 
the ZDV-experienced patient 8; at that time, CD4 cell 
count was 248 pg/mL and plasma HIV-l RNA levels were 
9600 copies/ml; the woman refused PI and NW? 
Every antiretroviral regimen, including highly active 
antiretroviral therapy (HAART), was well-tolerated 
during pregnancy by the 18 women and by the 24 new- 
borns. No short-term adverse effects were observed and 
follow-up of the infants is continuing. The adverse 
effects of fetal exposure to antiretroviral drugs are still 
unknown X* and long-term follow-up of all children 
exposed to antiretroviral therapy, beyond that initiated 
before pregnancy, is important with the increasing use 
of HAART. Actually, more women become pregnant 
while already on a combination of antiretroviral ther- 
apy, and there are still few data on the use of ZDV, the 
most used antiretroviral drug in pregnancy, in the first 
trimester of pregnancy. Studies suggest that ZDV may 
have a direct toxic effect on the developing mouse 
embryo in early stages of pregnancy5 
The optimal therapeutic regimen for HIV-l-infected 
pregnant women should be, as far as possible, the same 
as that for HIV-l-infected nonpregnant women; thus, 
ZDV cannot always be included as a component of the 
antiretroviral regimen in HIV-l-infected pregnant 
women. Actually ZDV-resistant strains of HIV-l, mea- 
sured by genetic analysis, appear to be an inevitable 
consequence of antiviral treatment for HIV-l, and viro- 
logic failure, dangerous for fetuses, is often associated 
with resistance. 
In conclusion, an antiretroviral regimen that does not 
include ZDV, in ZDV-experienced individuals, may be 
required in pregnancy too. Finally, there are no guidelines 
about the suitable therapeutic regimen or single drug 
(i.e., d4T or 3TC in pregnancy + NVP intrapartum) for 
pregnant women not on antiretrovirai therapy, ZDV mtol- 
erant women, or those unlikely to respond to ZDV (naive 
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Table 1. CD4 Cell Count, Viral Load, Antiretroviral Regimen, Mode of Delivery of Pregnant Women 
and Actual Infection and Clinical Status of the Children 
Children 
HIV-RNA 
Patient CD4/mL (copies/ml) Antiretroviral Regimen 
Mode of 
Delivery Note 
Current 
H/V PCR Clinical Status 
1 
1 
558 
692 
35,000 
1,800 
2 756 3,000 
3 1306 <50 
4 435 <50 
d4T-3TCNFV started before pregnancy 
ZDV-3TC started at 38 wk 
ZDV started at 14 wk 
ZDV started at 14 wk 
ZDV-STC-NFV at 6 wk 
5 348 4,700 d4T-3TC-IDV started before pregnancy 
6 639 <50 ZDV-3TC started at 14 wk 
7 615 3,700 ZDV-3TC started at 24 wk 
8 349 250 d4T-3TC started at 14 wk 
9 470 2,700 ZDV started at 14 wk 
10 601 4,000 ZDV-ddC started before pregnancy 
11 468 4,400 ZDV-STC-NVP started before pregnancy 
12 462 600 ZDV started at 14 wk 
13 1194 <50 
14 1090 120 
15 119 100,000 
16 1191 <50 
17 376 12,000 
18 442 1,900 
ZDV-3TC started at 25 wk 
ZDV-3TC started before pregnancy 
ZDV-3TC started before pregnancy 
ZDV-3TC started at 33 wk 
ZDV-NVP-NFV started at 33 wk 
ZDV-ddC-SQV started before pregnancy 
cs 
cs 
1 st pregnancy 
2nd pregnancy 
cs 
cs 
VD 
cs 
cs 
cs 
VD 
cs 
VD 
VD 
VD 
cs 
cs 
VD 
VD 
cs 
VD 
NFV stopped and NVP 
started at 15 wk 
HAART stopped between 
6and 14wk 
Twin birth 
Twin birth 
DDC stopped at 8 wk; 
pPROM 
ZDV not administered 
intrapartum 
Twin birth 
Triplet birth 
HIV+ 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
HIV- 
Trisomy 18 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
No AE 
ZDV = zidovudine; d4T = stavudine; 3TC = lamivudine; NFV = nelfinavir; IDV = indinavir; ddC = zalcitabine; NVP = nevirapine; SQV = saquinavir; CS = cesarean 
section; VD = vaginal delivery; HAART = highly active antiretroviral therapy; pPROM = preterm premature rupture of membranes; HIV PCR = human 
immunodeficiency virus poiymerase chain reaction; AE = adverse event: HIV+ = HIV-positive; HIV- = HIV-negative. 
with genotypic or phenotypic resistance to ZDV), who 
would not otherwise start antiviral therapy. 
REFERENCES 
1. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV- 
1 transmission: interaction between zidovudine prophylaxis 
and mode of delivery in the French perinatal cohort. JAMA 
1998; 280:55-60. 
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal- 
infant transmission of human immunodeficiency virus 
type 1 with zidovudine treatment. N Engl J Med 1994; 331: 
1173-1180. 
3. Antiretroviral Pregnancy Registry Advisory Committee. The 
antiretroviral pregnancy register January 1999. Interim 
Report 1999:l. 
4. Brinkman K, ter Hofstede HJM, Burger DM, Smeiting JAM, 
Koopmans PP. Adverse effects of reverse transcriptase 
inhibitors: mitochondrial toxicity as common pathway. AIDS 
1998; 12:1735-1744. 
5. Minkoff H, Augenbraun M. Antiretroviral therapy for preg- 
nant women. Am J Obstet Gynecol 1997; 176:478-489. 
6. Guay LA, Musoke P Fleming T, et al. Intrapartum and neonatal 
single-dose nevirapine compared with zidovudine for pre- 
vention of mother-to-child transmission of HIV-l in Kam- 
pala, Uganada. HlVNET 012 randomised trial. Lancet 1999; 
354795-802. 
